FinnGen
HeadquartersHelsinki, Finland
Websitehttps://www.finngen.fi/

The FinnGen project was launched in 2017 [1] with the aim of collecting biological samples from 500,000 participants in Finland over six years with the aim of improving health through genetic research.[2] This is about 10% of the population. It is hoped that it will be a springboard for better diagnostics and new therapies.[3] It is the key to Finland's Health Sector Growth Strategy for Research and Innovation Activities.

Activity

It is a public–private partnership between Finnish universities, the National Institute for Health and Welfare, the Finnish Red Cross Blood Service, the biobanks, which are mostly owned by independent hospital districts, hospitals, and pharmaceutical companies including Abbvie, AstraZeneca, Biogen, Celgene, Genentech, GSK, Janssen, Maze Therapeutics, Merck, Novartis, Pfizer, and Sanofi. It has funding of approximately €80 million, some of which has come from the companies.[4] €20 million has come from Business Finland. 500,000 blood samples are to be collected over six years by a nation-wide network of Finnish biobanks and they will be matched with national health records, 98% of which are available in an electronic format. It claims that it will manage the anonymous health registry and the genomic data without compromising the privacy and integrity of participants.[5]

The study is using Thermo Fisher Scientific's Axiom Genotyping Solution. In February 2021, the FinnGen data resource contained data from more than 321,000 biobank sample donors.

DNA samples had already been collected from about 230,000 Finns for earlier studies.[6] The 2013 Biobank Act permitted samples to be transferred to biobanks and made available to researchers. These earlier samples were collected from people who are now getting older, so they can be related to many more disease events than the UK Biobank. The concept of ‘broad consent’ means that participants do not have to be asked to consent for their samples to be used in each project. The Finnish Biobank Cooperative was established in 2017.[7] The first summary of results was released to the public on January 14, 2020 [8] and will be updated every 6 months, at a one year delay with the internal findings.

History

Finnish people descend from a small founder population with little consanguinity. The low level of variants in the population structure means the chances that any disease association findings will have statistical significance are greater. Genetic discoveries can be made more easily than in more heterogeneous populations.[9]

References

  1. ↑ "Finngen/en/Aboutus". Retrieved 26 November 2019.
  2. ↑ "FinnGen, a global research project focusing on genome data of 500,000 Finns, launched". EurekAlert!. American Association for the Advancement of Science. 2017-12-19. Retrieved 2018-02-03.
  3. ↑ "Massgeschneidert statt massentauglich". SRF. 21 November 2018. Retrieved 13 December 2018.
  4. ↑ "FinnGen study in a nutshell | FinnGen". www.finngen.fi. Retrieved 2019-11-23.
  5. ↑ "FINNGEN STUDY IN A NUTSHELL". Finngen. 2018. Retrieved 13 December 2018.
  6. ↑ "Finnish researchers to create DNA database of 500,000 people for disease studies". YLE. 17 January 2018. Retrieved 13 December 2018.
  7. ↑ "Biobanking in Finland: a success story". Health Europa. 8 November 2018. Retrieved 13 December 2018.
  8. ↑ "ACCESS RESULTS | FinnGen". www.finngen.fi. Retrieved 2020-05-19.
  9. ↑ "Thermo Fisher Scientific Custom Microarrays Drive Large-Scale Genotyping Study of Finnish Population". PR Newswire. 16 October 2018. Retrieved 13 December 2018.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.